Safety of Nintedanib in Treatment of Idiopathic Pulmonary Fibrosis: A Meta-analysis
Houyu YANG,Zong'an LIANG
DOI: https://doi.org/10.3969/j.issn.1006-2084.2017.17.038
2017-01-01
Abstract:Objective To evaluate the effectiveness of nintedanib in treatment of idiopathic pulmonary fibrosis (IPF).Methods Pubmed,Embase,Medline,CNKI,VIP Database,Wanfang Database till Feb.2017 were searched using the keywords nintedanib and idiopathic pulmonary fibrosis.Randomized controlled trials (RCT) of nintedanib in treatment of IPF were selected.The patients in the trial group were given nintedanib while the patients in the control group were given oral placebo.The primary end point of the outcome was the incidence of adverse events.The Meta-analysis was performed using RevMan 5.3.Results A total of 4 RCTs were enrolled.The incidences of many kinds of adverse events in the trial group were markedly lower than those in the control group,including progression of idiopathic pulmonary fibrosis [9.68％ (95/ 981) vs 14.2 ％ (72/508),RR =0.66,95 ％ CI 0.48-0.93,P =0.02],cardiac disorder [1.22％ (12/981) vs 2.56％ (13/508),RR =0.41,95％ CI 0.19-0.91,P =0.03],fatal adverse event[5.81％ (57/981) vs 8.46％ (43/508),RR =0.64,95％ 0.42-0.97,P =0.04].However,there was no statistical significant difference in treatment-related serious events including cough [14.4％ (141/981) vs 14.6％ (74/508),RR =0.93,95％ CI 0.68-1.27,P =0.64],bronchitis [11.2％ (110/981) vs 11.0％ (56/508),RR =0.98,95％ CI 0.69-1.39,P =0.91],nasopharyngitis [13.3 ％ (90/676) vs 15.6％ (68/435),RR =0.84,95％ CI 0.60-1.18,P =0.32],dyspnea [9.07％ (89/981) vs 11.6％ (59/508),RR =0.70,95％ CI 0.49-1.01,P =0.06],serious adverse events [28.0％ (285/1 019) vs 29.4％ (153/520),RR =0.97,95 ％ CI 0.77-1.23,P =0.81],adverse event leading to study discontinuation [19.5％ (199/1019) vs 14.8％ (77/520),RR =1.33,95％ CI 0.99-1.77,P =0.33].Conclusion The adverse events are mild and mostly recoverable without obvious sequelae,so nintedanib is safe and well-tolerated.